Dr Reddy’s Laboratories has requested the US Food and Drug Administration (FDA) schedule an inspection of the firm’s oncology formulation manufacturing facility in Duvvada, Andhra Pradesh, India, as part of the firm’s ongoing attempts to resolve agency concerns at the firm’s two warning letter-stricken plants.
Alongside the Duvvada facility, Reddy’s active pharmaceutical ingredient (API) manufacturing facility in Srikakulam, Andhra Pradesh, continues to be restrained by...




